Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

F) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014 /PRNewswire/ ... operates in Southern California , today ... caregiving technology. Alta will be providing the innovative BeClose ... services. Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... to providing the kind of affordable 24/7 care our ...
(Date:11/21/2014)... Nov. 21, 2014  World Hemp Oil, an importer ... announces they are now offering legal, organic oil with ... type strains grown in medical marijuana states. People suffering ... such as Parkinson,s, MS, and spinal cord injury, no ... pass, because imported CBD Oil Is legal in all ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... ECRI Institute ®, an independent nonprofit that researches the ... of PriceGuide 4.0 , the latest generation of ... medical-surgical supplies and implants.   (Logo: ... a whole new level of interactivity and functionality for ...
... We applaud Gov. Rick Snyder for his efforts to put ... As the Governor stated, "the state of Michigan currently ... of 31.7 percent." It also has the sixth-highest rate of ... high rates of chronic conditions, Michiganders also appear to suffer ...
Cached Medicine Technology:New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 3Statement from the Michigan Society of Anesthesiologists in Response to Governor Snyder's Health & Wellness Announcement 2
(Date:11/24/2014)... Dr. Michael Kettel , a leading fertility expert ... to discuss egg freezing as a viable and increasingly accessible ... news recently, with new company benefits at Facebook and Apple ... “[The companies] see it as a way to take care ... Says Dr. Kettel. , Up until a few weeks ago, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a famous wedding ... for many products, especially the beautiful colored wedding dresses ... with amazing discounts, up to 90% off. Don’t hesitate ... easy to buy colored wedding dresses in different sizes ... famous for delicate craftsmanship, elegant style and perfect lines. ...
(Date:11/23/2014)... November 24, 2014 Tbdress.com has ... available online on Nov. 28, 2014. The special offer will ... , Tbdress.com is one of the world’s largest women’s dresses ... and colors. People can enjoy great discounts on that day: ... enjoy free delivery (for orders above $89). , People can ...
(Date:11/23/2014)... November 23, 2014 Nearly 260 ... attacks, strokes, deep vein thrombosis and other serious ... federal multidistrict litigation (MDL) underway in the Northern ... , Court documents updated on November 17th by ... show the filing of 259 lawsuits against the ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... French . , , Montreal, May 22, 2008 ... first trimester, according to a new study from the Universit ... edition of the British Journal of Psychiatry. , Dr. ... effect on foetal development. This is the first study to ...
... PartnerRe Ltd.,(NYSE: PRE ) today announced that ... Finance A LLC, $250 million of,10-year fixed rate 6.875% ... The Senior Notes will be fully and,unconditionally guaranteed by ... of the proceeds from the offering to,repay all of ...
... Distributor to Expand Global Reach of Novel Technology, ... Bioscience,leaders in real-time measurement of cellular bioenergetics, announced ... of Seahorse,XF instruments and consumables in Japan., ... continuing to,grow, as we have seen with the ...
... NYER ) reported results for the third quarter of ... 2008 increased $1.55,million or 8.9% to $18.92 million from $17.38 ... for the three months ended March 31, 2008,was $615,892 or ... $67,919 or $.02,per share for the same period ended March ...
... letter to Congress today about ,Breast Cancer Patient Protection ACT, ... ... WASHINGTON, May 22 "Mandatory drive-through,mastectomies is an unconscionable practice that ... Weiss, a,leading breast oncologist and Founder and President of Breastcancer.org, in,an ...
... national fats awareness campaign with ... ,Better Fats Sisters, ... "better" fats (monounsaturated and polyunsaturated) can help reduce,their risk of heart ... To view the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/aha/33320/ ...
Cached Medicine News:Health News:PartnerRe Ltd. to Issue $250 million in 6.875% Senior Notes 2Health News:PartnerRe Ltd. to Issue $250 million in 6.875% Senior Notes 3Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008 3Health News:Drive-Through Mastectomies Threaten Patients' Lives 2Health News:Video: Most Americans Don't Know 'Better Fats' Benefit Heart Health 2Health News:Video: Most Americans Don't Know 'Better Fats' Benefit Heart Health 3
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: